Cystic fibrosis, a genetic disorder, affects lungs and other organs. It causes thick mucus buildup. Researchers have ...
In the last few years, progress has been made in the fight against Alzheimer's disease with a class of therapies called ...
Glioblastoma is the most common form of brain cancer in adults, and its consequences are usually quick and fatal. After ...
Confused about protein recommendations? We asked protein experts on what exactly is the answer. Plus, everything else you ...
In addition to CG001419, Cullgen continues the advancement of CG009301, a GSPT1 degrader being studied in a Phase 1 trial for the treatment of blood cancers, as well as progressing its pipeline of pre ...
HIGHLIGHTSAn additional confirmed partial response has been recorded in the ongoing ACCENT trialThis brings the confirmed Objective Response Rate ...
Patients whose cancers were hormone receptor (HR) negative – that is, their tumor cells did not have proteins that bind to ...
Two scientists at the Johns Hopkins School of Medicine have been selected for membership in the National Academy of Inventors ...
This research led to Balu-Iyer founding the Buffalo-based company Immune Modulatory Therapies LLC in 2019. His UB co-founders ...
The first-line standard of care for HR-positive/HER2-negative breast cancer is cyclin-dependent kinase (CDK)4/6 inhibitors ...
Trastuzumab deruxtecan (T-DXd; Enhertu), is a HER2-targeting ADC that is used in ET-treated HER2-low or HER2-ultralow disease and offered meaningful results in DESTINY-Breast04. In a 2025 real-world ...
Explore the full archive of TIME, a century of journalism, insight, and perspective, with AI that helps you research, connect ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback